# Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

> **NCT01228019** · — · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1166 (actual)

## Conditions studied

- Hypercholesterolemia
- Mixed Dyslipidemia

## Interventions

- **DRUG:** Niacin (+) laropiprant

## Key facts

- **NCT ID:** NCT01228019
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 1166 (ACTUAL)
- **Why stopped:** In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs
- **Last updated:** 2015-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228019, "Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01228019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*